Current Report Filing (8-k)
May 12 2022 - 4:15PM
Edgar (US Regulatory)
0000876343
false
0000876343
2022-05-12
2022-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 12, 2022
Lineage
Cell Therapeutics, Inc.
(Exact
name of registrant as specified in charter)
California |
|
001-12830 |
|
94-3127919 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2173
Salk Avenue, Suite 200
Carlsbad,
California |
|
92008 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(442)
287-8990
Registrant’s
telephone number, including area code
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock |
|
LCTX |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
May 12, 2022, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2022,
a copy of which is furnished as Exhibit 99.1.
The
information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any
filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in
such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Lineage
Cell Therapeutics, Inc. |
|
|
|
Date:
May 12, 2022 |
By:
|
/s/
George A. Samuel III |
|
Name:
|
George
A. Samuel III |
|
Title: |
General
Counsel and Corporate Secretary |
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024